PMID- 24738942
OWN - NLM
STAT- MEDLINE
DCOM- 20160401
LR  - 20191210
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 56
IP  - 2
DP  - 2015 Feb
TI  - Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin 
      lymphoma: a first comprehensive approach to determine cognitive impairments after 
      treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and 
      prednisone or rituximab and bendamustine.
PG  - 347-52
LID - 10.3109/10428194.2014.915546 [doi]
AB  - To assess the effects of chemoimmunotherapy on post-chemotherapy cognitive 
      impairments (PCCI) in patients with B-cell non-Hodgkin lymphoma (NHL), we used 
      objective and subjective measures of cognitive functions in combination with 
      serum parameters and neuroelectric recordings. Self-perceived status of 
      cognition, fatigue and emotional functioning were reduced in patients (n=30) 
      compared to healthy controls (n=10). Cognitive performance was impaired in 
      patients with NHL compared to controls and a norm sample (n=1179). PCCI was more 
      severe in patients treated with rituximab and bendamustine (BR) than in patients 
      who received R in combination with CHOP (cyclophosphamide, doxorubicin, 
      vincristine, prednisone) polychemotherapy (R-CHOP). Individual alpha peak 
      frequency and serum brain-derived neurotrophic factor (BDNF) levels in patients 
      with NHL correlated with accuracy in the objective cognition test. Higher serum 
      interleukin-6 (IL-6) concentrations were associated with higher fatigue levels. 
      Patients with NHL and especially those who were treated with BR were affected by 
      PCCI. BDNF and IL-6 might be involved in the pathogenesis of PCCI and fatigue.
FAU - Zimmer, Philipp
AU  - Zimmer P
AD  - Department for Molecular and Cellular Sports Medicine.
FAU - Mierau, Andreas
AU  - Mierau A
FAU - Bloch, Wilhelm
AU  - Bloch W
FAU - Struder, Heiko K
AU  - Struder HK
FAU - Hulsdunker, Thorben
AU  - Hulsdunker T
FAU - Schenk, Alexander
AU  - Schenk A
FAU - Fiebig, Leonie
AU  - Fiebig L
FAU - Baumann, Freek T
AU  - Baumann FT
FAU - Hahn, Moritz
AU  - Hahn M
FAU - Reinart, Nina
AU  - Reinart N
FAU - Hallek, Michael
AU  - Hallek M
FAU - Elter, Thomas
AU  - Elter T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140605
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Interleukin-6)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 981Y8SX18M (Bendamustine Hydrochloride)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - B-Lymphocytes/*drug effects/pathology
MH  - Bendamustine Hydrochloride/administration & dosage/adverse effects
MH  - Brain-Derived Neurotrophic Factor/blood
MH  - Cognition Disorders/chemically induced/*diagnosis
MH  - Cyclophosphamide/administration & dosage/adverse effects
MH  - Doxorubicin/administration & dosage/adverse effects
MH  - Electroencephalography
MH  - Fatigue/chemically induced/diagnosis
MH  - Female
MH  - Humans
MH  - Interleukin-6/blood
MH  - Lymphoma, Non-Hodgkin/blood/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care/methods
MH  - Prednisone/administration & dosage/adverse effects
MH  - Rituximab/administration & dosage/adverse effects
MH  - Surveys and Questionnaires
MH  - Vincristine/administration & dosage/adverse effects
OTO - NOTNLM
OT  - Chemobrain
OT  - EEG
OT  - cognition
OT  - cytokines
OT  - fatigue
OT  - lymphoma
EDAT- 2014/04/18 06:00
MHDA- 2016/04/02 06:00
CRDT- 2014/04/18 06:00
PHST- 2014/04/18 06:00 [entrez]
PHST- 2014/04/18 06:00 [pubmed]
PHST- 2016/04/02 06:00 [medline]
AID - 10.3109/10428194.2014.915546 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2015 Feb;56(2):347-52. doi: 10.3109/10428194.2014.915546. Epub 
      2014 Jun 5.